Skip to content
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Neuromuscular medicine

Prednisone vs Deflazacort vs Vamorolone: Which for DMD?

At a Glance

Prednisone, deflazacort, and vamorolone can all slow muscle decline in Duchenne muscular dystrophy, but no option is best for every child. The choice depends on motor function, age, side effects, growth and bone concerns, safety planning, and access.

Prednisone, deflazacort (Emflaza), and vamorolone (Agamree) are effective corticosteroid medications used to slow muscle decline and prolong walking in children with Duchenne muscular dystrophy (DMD) [1][2]. While all three drugs provide vital motor benefits, they come with different side effect profiles—particularly regarding weight gain, bone health, and growth [3][4].

No single option is universally best for every child. Choosing the right medication is a shared decision based on your child’s age, current function, side effect tolerability, and insurance coverage.

Slowing Muscle Decline

All three medications help delay the progression of muscle weakness, but definitive, long-term evidence comparing all three directly is limited [1][2].

  • Prednisone and Deflazacort: In a rigorous 3-year head-to-head clinical trial (the FOR-DMD study), daily prednisone and daily deflazacort performed very similarly in preserving motor function [1]. Some long-term observational data suggest deflazacort might delay the loss of walking slightly longer than prednisone, but these results may be influenced by differences in how the studies were conducted, baseline age, or how long patients stayed on the medication [5][6].
  • Vamorolone: Approved in 2023 for children aged 2 and older, vamorolone is a newer medication designed to work similarly to traditional steroids but with fewer side effects [7]. Short-term trials (24 to 48 weeks) and extension studies show it improves and maintains motor outcomes compared to a placebo [2][8]. However, because it is newer, we do not yet have the years-long head-to-head data to prove it preserves walking for as long as the older steroids.

Standard Dosing

These medications are prescribed as a daily oral dose based on your child’s weight. Never adjust or switch doses yourself, as your physician must carefully calculate and adjust the regimen as your child grows.

  • Prednisone: Typically given at 0.75 mg/kg (milligrams per kilogram of body weight) per day [9]. While standard of care in DMD clinics, it is not FDA-approved specifically for DMD [10].
  • Deflazacort: Usually dosed at 0.9 mg/kg per day [11][1]. It is officially FDA-approved for DMD.
  • Vamorolone: The standard recommended dose is 6 mg/kg per day [7][2]. In specific circumstances, a lower dose of 2 mg/kg per day may be considered, but these are not interchangeable routine doses [2].

Comparing Side Effects

The most significant differences between these medications emerge when looking at their side effects.

Summary Comparison Table

Feature Prednisone Deflazacort Vamorolone
Usual Dose ~0.75 mg/kg/day [9] 0.9 mg/kg/day [1] 6 mg/kg/day [2]
Evidence Strength Proven long-term (3-year direct trial) [1] Proven long-term (3-year direct trial) [1] Short-term trials vs placebo (up to 48 weeks) [8]
Weight Effects High risk; more weight gain than deflazacort [12] Lower risk than prednisone [12] Risk present; indirect studies show BMI increases [3]
Growth Reduces growth velocity [2] Reduces growth velocity [13] Growth-sparing (protects velocity) [2]
Bone/Fractures High risk of fractures [2] High risk; highest in some observational data [14] Improves lab biomarkers; fracture risk remains [2]
Cataracts Can cause cataracts [15] Higher associated risk than prednisone [15] Unknown / developing long-term data
Behavior Common (mood swings, irritability) [1] Common, roughly similar to prednisone [1] Preliminary data suggests fewer issues [16]
Adrenal Risk Suppresses adrenal function [17] Suppresses adrenal function [17] Suppresses adrenal function [18]

Weight Gain

Weight gain is a common challenge. In head-to-head trials, prednisone caused significantly more weight gain than deflazacort [12][3]. While vamorolone was developed to reduce side effects, it is not weight-neutral. In indirect comparisons across different studies, children taking vamorolone experienced increases in Body Mass Index (BMI) that were sometimes higher than those on standard steroids, though BMI can be difficult to interpret when height is also changing [3][4].

Linear Growth (Height)

Standard steroids (prednisone and deflazacort) frequently reduce growth velocity, leading to a shorter predicted adult height [2][13]. Vamorolone is associated with better growth velocity and appears to be “growth-sparing,” making it a preferable option for families highly concerned about stature [2][3]. Please note that DMD itself, as well as delayed puberty, can also affect a child’s natural growth.

Bone Health and Fractures

Fragile bones are a major concern in DMD. While vamorolone appears gentler on certain laboratory bone-turnover biomarkers than prednisone [2], improved biomarkers do not guarantee fewer fractures. Deflazacort has been associated with high fracture rates in some observational studies, though it is unclear if this is due to the drug itself or because patients tend to take it for a longer duration [14].

Important: Vertebral (spine) fractures can be “silent” and painless [19]. Regardless of the medication, your child will need routine bone monitoring, including DXA scans and spinal imaging, as well as vitamin D and calcium assessments [20][21]. Sudden back pain, height loss, or an unexplained decline in mobility warrants a prompt medical assessment.

Behavior and Eye Health

Behavioral changes—such as mood swings, irritability, or aggression—are common with both prednisone and deflazacort, occurring at roughly similar rates depending on how they are measured [1]. Preliminary data suggests vamorolone might cause fewer behavioral issues, but this is not yet a guaranteed benefit [16]. Report urgent changes like extreme aggression, severe insomnia, hallucinations, or safety concerns to your doctor immediately.

Additionally, all systemic steroids can cause cataracts, though some studies link deflazacort to a higher risk than prednisone [15]. Annual, routine eye exams are essential for any child taking these medications [22].

Other Routine Steroid Side Effects

Children on any of these medications require monitoring for elevated blood pressure, blood sugar changes, delayed puberty, gastrointestinal symptoms, and an increased risk of infections [23]. Always consult your care team before giving your child live vaccines.

The Adrenal Warning (Crucial Safety Plan)

It is absolutely critical to understand that all three medications suppress the body’s natural ability to make cortisol (a condition called adrenal suppression) [18]. Cortisol is the stress hormone that helps the body survive physical trauma, fever, and severe illness.

  • Never Stop Abruptly: You must never stop or independently taper these medications. Doing so can cause a life-threatening adrenal crisis [17]. If a dose is missed, follow your doctor’s exact instructions for making it up.
  • Emergency “Stress Dosing”: If your child experiences a severe illness (like high fever), trauma, or requires surgery, they will need higher “stress doses” of steroids to help their body cope [24].
  • Vomiting is an Emergency: If your child is repeatedly vomiting and cannot keep their oral steroid pill down, you must go to the emergency room immediately to receive intravenous (IV) or injectable steroids.
  • Action Steps: Ask your doctor for a written, medication-specific stress-dose plan. Keep emergency injectable hydrocortisone on hand if prescribed, ensure your child wears a medical alert bracelet, and share this plan clearly with their school and other caregivers.

Common questions in this guide

Which steroid is best for a child with Duchenne muscular dystrophy?
There is no single best steroid for every child. Prednisone, deflazacort, and vamorolone can all support motor function, and the choice depends on age, current function, side effects, growth and bone concerns, and insurance coverage.
How do prednisone, deflazacort, and vamorolone differ in weight and growth effects?
Prednisone generally causes more weight gain than deflazacort. Vamorolone appears to better preserve height growth, but it is not free of weight gain, and long-term comparisons with the older steroids are limited.
What are the usual daily doses of these DMD steroids?
Common weight-based doses are about 0.75 mg/kg/day for prednisone, 0.9 mg/kg/day for deflazacort, and 6 mg/kg/day for vamorolone. A child's clinician must calculate and adjust the dose as the child grows, so families should not change or switch doses on their own.
Can a child stop prednisone, deflazacort, or vamorolone suddenly?
No. All three can suppress the body's cortisol production, so stopping suddenly or changing the dose without medical guidance can cause a life-threatening shortage of cortisol called an adrenal crisis. The care team should provide a tapering and emergency stress-dose plan.
What should I do if my child cannot keep a DMD steroid down because of vomiting?
Repeated vomiting that prevents a child from keeping an oral steroid down is an emergency because the body may need steroid medicine quickly. Go to the emergency room for injectable or intravenous steroids and follow the written stress-dose instructions from the child's care team.
What monitoring does a child need while taking a DMD steroid?
Monitoring may include growth, weight, blood pressure, blood sugar, behavior, infection risk, regular eye exams, and bone health. Bone follow-up can include vitamin D and calcium checks, bone-density DXA scans, and spinal imaging because spine fractures may occur without pain.

Get notified when new evidence is published on Duchenne muscular dystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (24)
  1. 1

    Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.

    Guglieri M, Bushby K, McDermott MP, et al.

    JAMA 2022; (327(15)):1456-1468 doi:10.1001/jama.2022.4315.

    PMID: 35381069
  2. 2

    Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.

    Guglieri M, Clemens PR, Perlman SJ, et al.

    JAMA neurology 2022; (79(10)):1005-1014 doi:10.1001/jamaneurol.2022.2480.

    PMID: 36036925
  3. 3

    Vamorolone for Duchenne Muscular Dystrophy: A Cross-Trial Efficacy Comparison With Classic Corticosteroids From the FOR-DMD Trial.

    Clemens PR, Berglund A, Schiava M, et al.

    Neurology 2026; (107(1)):e214756 doi:10.1212/WNL.0000000000214756.

    PMID: 42202243
  4. 4

    Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy.

    Biggar WD, Skalsky A, McDonald CM

    Journal of neuromuscular diseases 2022; (9(4)):463-476 doi:10.3233/JND-210776.

    PMID: 35723111
  5. 5

    Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center.

    Marden JR, Freimark J, Yao Z, et al.

    Journal of comparative effectiveness research 2020; (9(3)):177-189 doi:10.2217/cer-2019-0170.

    PMID: 31922454
  6. 6

    Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.

    McDonald CM, Sajeev G, Yao Z, et al.

    Muscle & nerve 2020; (61(1)):26-35 doi:10.1002/mus.26736.

    PMID: 31599456
  7. 7

    Vamorolone: First Approval.

    Keam SJ

    Drugs 2024; (84(1)):111-117 doi:10.1007/s40265-023-01986-2.

    PMID: 38103149
  8. 8

    Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial.

    Dang UJ, Damsker JM, Guglieri M, et al.

    Neurology 2024; (102(5)):e208112 doi:10.1212/WNL.0000000000208112.

    PMID: 38335499
  9. 9

    Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of Neurology.

    Gloss D, Moxley RT, Ashwal S, Oskoui M

    Neurology 2016; (86(5)):465-72 doi:10.1212/WNL.0000000000002337.

    PMID: 26833937
  10. 10

    Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models.

    Liu G, Lipari P, Mollin A, et al.

    Human molecular genetics 2024; (33(3)):211-223 doi:10.1093/hmg/ddad173.

    PMID: 37819629
  11. 11

    A Review of Deflazacort for Patients With Duchenne Muscular Dystrophy.

    Bylo M, Farewell R, Coppenrath VA, Yogaratnam D

    The Annals of pharmacotherapy 2020; (54(8)):788-794 doi:10.1177/1060028019900500.

    PMID: 32019318
  12. 12

    Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.

    Griggs RC, Miller JP, Greenberg CR, et al.

    Neurology 2016; (87(20)):2123-2131 doi:10.1212/WNL.0000000000003217.

    PMID: 27566742
  13. 13

    Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.

    Lamb MM, West NA, Ouyang L, et al.

    The Journal of pediatrics 2016; (173()):207-213.e3.

    PMID: 27039228
  14. 14

    Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.

    Joseph S, Wang C, Bushby K, et al.

    JAMA neurology 2019; (76(6)):701-709 doi:10.1001/jamaneurol.2019.0242.

    PMID: 30855644
  15. 15

    Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients.

    Rice ML, Wong B, Horn PS, Yang MB

    Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 2018; (22(3)):192-196 doi:10.1016/j.jaapos.2018.01.017.

    PMID: 29733899
  16. 16

    Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.

    Smith EC, Conklin LS, Hoffman EP, et al.

    PLoS medicine 2020; (17(9)):e1003222 doi:10.1371/journal.pmed.1003222.

    PMID: 32956407
  17. 17

    A structured approach to address variability in the global management of adrenal insufficiency in Duchenne muscular dystrophy: the 2025 PJ Nicholoff steroid protocol.

    Sbrocchi AM, Ahmet A, Kinnett K, et al.

    Frontiers in neurology 2026; (17()):1926817 doi:10.3389/fneur.2026.1926817.

    PMID: 42787106
  18. 18

    Adrenal Suppression From Vamorolone and Prednisone in Duchenne Muscular Dystrophy: Results From the Phase 2b Clinical Trial.

    Ahmet A, Tobin R, Dang UJ, et al.

    The Journal of clinical endocrinology and metabolism 2025; (110(2)):334-344 doi:10.1210/clinem/dgae521.

    PMID: 39097643
  19. 19

    Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment.

    Wong BL, Rybalsky I, Shellenbarger KC, et al.

    The Journal of pediatrics 2017; (182()):296-303.e1 doi:10.1016/j.jpeds.2016.11.078.

    PMID: 28043681
  20. 20

    Optimizing Bone Health in Duchenne Muscular Dystrophy.

    Buckner JL, Bowden SA, Mahan JD

    International journal of endocrinology 2015; (2015()):928385 doi:10.1155/2015/928385.

    PMID: 26124831
  21. 21

    Growth, pubertal development, and skeletal health in boys with Duchenne Muscular Dystrophy.

    Ward LM, Weber DR

    Current opinion in endocrinology, diabetes, and obesity 2019; (26(1)):39-48 doi:10.1097/MED.0000000000000456.

    PMID: 30507696
  22. 22

    Managing growth and puberty concerns in individuals with Duchenne muscular dystrophy: Updated guidance and future directions.

    Rutter MM, Crane JL, Babalola F, et al.

    Journal of neuromuscular diseases 2026; 22143602261486896 doi:10.1177/22143602261486896.

    PMID: 42857968
  23. 23

    Observational study of changes to glucocorticosteroid prescribing patterns in duchenne muscular dystrophy in the UK over the last decade.

    Landon G, Stimpson G, Guglieri M, et al.

    Journal of neurology, neurosurgery, and psychiatry 2025; (96(8)):794-801 doi:10.1136/jnnp-2024-335223.

    PMID: 39939137
  24. 24

    Adrenal Suppression in Duchenne Muscular Dystrophy: Management Strategies Incorporating Novel Steroid Vamorolone.

    Sbrocchi AM, Kinnett K, Lautatzis ME, et al.

    Journal of the Endocrine Society 2026; (10(2)):bvaf181 doi:10.1210/jendso/bvaf181.

    PMID: 41509125

This comparison is for informational purposes only and does not constitute medical advice. Do not change, stop, or switch your child's steroid without a clinician's plan, because adrenal suppression can be dangerous.